Kestra Medical Technologies (NASDAQ: KMTS) insider plans sale of 26,287 shares via Form 144

Rhea-AI Filing Summary

Kestra Medical Technologies, Ltd. filed a notice of proposed sale of restricted securities. The filing covers a planned sale of 26,287 shares of common stock through Merrill Lynch, with an aggregate market value of $680,383.99, when the issuer had approximately 58,602,497 shares of common stock outstanding. The securities relate to performance share unit awards that vested on July 14, 2026 and were granted under the issuer’s equity compensation plan.

The reporting security holder, Vaseem Mahboob, also lists prior sales of common stock during the past three months: 3,980 shares on July 30, 2026 for $90,560.62; 8,817 shares on July 31, 2026 for $199,344.62; 5,391 shares on August 3, 2026 for $128,312.27; and 6,995 shares on August 4, 2026 for $172,634.70.

Key Figures

Proposed shares to be sold: 26,287 shares Aggregate market value of proposed sale: $680,383.99 Shares outstanding: 58,602,497 shares +4 more

7 metrics

Proposed shares to be sold 26,287 shares Common stock covered by the Form 144 notice

Aggregate market value of proposed sale $680,383.99 Value of 26,287 shares of common stock

Shares outstanding 58,602,497 shares Approximate common shares of Kestra Medical Technologies outstanding

Sale on 07/30/2026 3,980 shares for $90,560.62 Past 3-month common stock sale by Vaseem Mahboob

Sale on 07/31/2026 8,817 shares for $199,344.62 Past 3-month common stock sale by Vaseem Mahboob

Sale on 08/03/2026 5,391 shares for $128,312.27 Past 3-month common stock sale by Vaseem Mahboob

Sale on 08/04/2026 6,995 shares for $172,634.70 Past 3-month common stock sale by Vaseem Mahboob

Key Terms

Form 144, performance share unit awards, equity compensation plan

3 terms

Form 144 regulatory

"filed a notice of proposed sale of restricted securities"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

performance share unit awards financial

"Vesting of performance share unit awards"

equity compensation plan financial

"Granted as part of issuer equity compensation plan"

A plan by which a company gives employees, directors or contractors ownership or the right to buy ownership in the company through stock, options or similar awards — think of promising slices of the company pie as part of someone's pay. It matters to investors because these awards can change the number of shares outstanding, affect reported profits and influence management’s decisions; large or generous plans can dilute existing holders and alter incentives over time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/07/2026 - 04:08 PM Accepted by SEC EDGAR 08/07/2026 - 04:07 PM Learn about SEC filing dates

FAQ

What does the Form 144 filing by KMTS relate to?

The Form 144 filing relates to a proposed sale of 26,287 shares of Kestra Medical Technologies common stock with an aggregate market value of $680,383.99, originating from vested performance share unit awards under the company’s equity compensation plan.

How many KMTS shares are proposed to be sold by Vaseem Mahboob?

Vaseem Mahboob is listed as proposing to sell 26,287 shares of Kestra Medical Technologies common stock. These shares are to be sold through Merrill Lynch and are tied to vested performance share unit awards granted under the issuer’s equity compensation plan.

What is the approximate market value of the KMTS shares in the proposed Form 144 sale?

The proposed sale covers KMTS common stock with an aggregate market value of $680,383.99. This value is associated with the 26,287 shares of common stock that are referenced in the Form 144 notice for potential sale through Merrill Lynch.

How many Kestra Medical Technologies (KMTS) shares were outstanding at the time of the Form 144?

At the time referenced, Kestra Medical Technologies had approximately 58,602,497 shares of common stock outstanding. This outstanding share count provides context for the 26,287 shares covered by the proposed sale in the Form 144 filing.

What KMTS stock sales has Vaseem Mahboob made in the past three months?

The filing lists past sales of KMTS common stock by Vaseem Mahboob: 3,980 shares on July 30, 2026 for $90,560.62, 8,817 shares on July 31, 2026 for $199,344.62, 5,391 shares on August 3, 2026 for $128,312.27, and 6,995 shares on August 4, 2026 for $172,634.70.

What is the origin of the KMTS shares covered in the proposed Form 144 sale?

The KMTS shares in the proposed sale come from performance share unit awards that vested on July 14, 2026. These awards were granted as part of the issuer’s equity compensation plan, and are now eligible to be sold subject to applicable securities rules.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch 225 Liberty Street Floor 37 New York NY 10281	26287	680383.99	58602497	08/07/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	07/14/2026	Vesting of performance share unit awards	KESTRA MEDICAL TECHNOLOGIES, LTD.			26287	07/14/2026	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Vaseem Mahboob 3933 LAKE WASHINGTON BLVD NE SUITE 200 KIRKLAND WA 98033	Common Stock	07/30/2026	3980	90560.62
Vaseem Mahboob 3933 LAKE WASHINGTON BLVD NE SUITE 200 KIRKLAND WA 98033	Common Stock	07/31/2026	8817	199344.62
Vaseem Mahboob 3933 LAKE WASHINGTON BLVD NE SUITE 200 KIRKLAND WA 98033	Common Stock	08/03/2026	5391	128312.27
Vaseem Mahboob 3933 LAKE WASHINGTON BLVD NE SUITE 200 KIRKLAND WA 98033	Common Stock	08/04/2026	6995	172634.70

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)